Johnson & Johnson (JNJ)
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find
Johnson & Johnson (JNJ -1.94%) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62 years in a row.
Earnings Picture Remains Strong: A Closer Look
The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters.
Earnings Picture Remains Strong: A Closer Look
The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters.
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson's nasal spray, Spravato (esketamine), to treat major depressive disorder.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations but broadly met revenue targets; full-year 2024 showed 4.3% sales growth and $5.79 EPS. Despite short-term challenges, including Stelara's patent loss, JNJ's long-term growth strategy focuses on high-growth markets and promising pipeline products. JNJ's MedTech division showed strong performance, with significant investments in cardiovascular and surgical robotics expected to drive future growth.
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Terence Flynn - Morgan Stanley Joshua Jennings - TD Cowen Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan David Roman - Goldman Sachs Operator Good morning and welcome to Johnson & Johnson's Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance
JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.
Johnson & Johnson slides as soft sales guidance casts shadow
Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over expectation-beating fourth-quarter profit. Adjusted net earnings of US$4.95 billion were down 11.1% year on year in the fourth quarter, J&J reported, but ahead of consensus expectations for US$4.88 billion.
Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Trump Tariffs Take Shape, Stargate AI Project Ramps Up, JNJ & PG Beat
Kevin Green joins Morning Movers to look at how President Trump's tariffs plan could impact several areas of the market, specifically currencies and copper. Then, the focus shifts to Trump's ambitious A.I.
